---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002731"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:55:22.923206+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences reports ~$868M FY2025 WAKIX revenue; guides $1.0-1.04B in 2026

## Summary
- Preliminary Q4 2025 WAKIX net revenue ~$243M; FY2025 ~$868M, up ~21% YoY.
- 2026 WAKIX net revenue guidance of $1.0-1.04B, on track for blockbuster status.
- Pitolisant GR NDA submission expected 2Q 2026; PDUFA 1Q 2027; aims to extend franchise into 2040s.
- Five ongoing Phase 3 reg. trials in CNS; topline data for pitolisant HD and EPX-100 in 2027.
- ZYN002 program in Fragile X discontinued; 22q deletion syndrome indication no longer pursued.

## SEC filing metadata
- accession: 0001104659-26-002731
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/0001104659-26-002731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/hrmy-20260112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002731
- JSON: https://secwatch.observer/filing/0001104659-26-002731.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.